Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Jun;37(6):1259–1263. doi: 10.1128/aac.37.6.1259

Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.

H Tomioka 1, H Saito 1, K Sato 1
PMCID: PMC187950  PMID: 8392307

Abstract

AM-1155 is a newly synthesized 6-fluoro-8-methoxy quinolone. We assessed its in vitro antimycobacterial activity using sparfloxacin (SPFX) and ofloxacin (OFLX) as comparison drugs. The MICs of these agents for various mycobacterial strains were determined by the agar dilution method with 7H11 medium. AM-1155 had lower MICs for 50 and 90% of tested strains of Mycobacterium kansasii, M. marinum, and M. fortuitum-M. chelonae complex than SPFX and OFLX, and the values for M. tuberculosis, M. scrofulaceum, and the M. avium-M. intracellulare complex were similar to those of SPFX and considerably lower than those of OFLX. In addition, the antimicrobial activity of AM-1155 against M. tuberculosis and M. intracellulare phagocytosed into murine peritoneal macrophages was compared with that of OFLX. AM-1155 (1 microgram/ml) inhibited the intracellular growth of both M. tuberculosis and M. intracellulare, whereas OFLX at the same concentration failed to show any such effect. Moreover, AM-1155 (10 micrograms/ml) exhibited a steady bactericidal action against M. tuberculosis, whereas OFLX at the same concentration had only a weak effect. AM-1155 (10 micrograms/ml) also inhibited the growth of M. intracellulare more effectively than OFLX.

Full text

PDF
1259

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Fuchs P. C. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob Agents Chemother. 1991 May;35(5):955–960. doi: 10.1128/aac.35.5.955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chin N. X., Gu J. W., Yu K. W., Zhang Y. X., Neu H. C. In vitro activity of sparfloxacin. Antimicrob Agents Chemother. 1991 Mar;35(3):567–571. doi: 10.1128/aac.35.3.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983 Nov;24(5):784–786. doi: 10.1128/aac.24.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gorzynski E. A., Gutman S. I., Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother. 1989 Apr;33(4):591–592. doi: 10.1128/aac.33.4.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Heifets L. B., Lindholm-Levy P. J. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Tubercle. 1987 Dec;68(4):267–276. doi: 10.1016/0041-3879(87)90067-5. [DOI] [PubMed] [Google Scholar]
  6. Hooper D. C., Wolfson J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 1985 Nov;28(5):716–721. doi: 10.1128/aac.28.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hosaka M., Yasue T., Fukuda H., Tomizawa H., Aoyama H., Hirai K. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob Agents Chemother. 1992 Oct;36(10):2108–2117. doi: 10.1128/aac.36.10.2108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ichiyama S., Tsukamura M. Ofloxacin and the treatment of pulmonary disease due to Mycobacterium fortuitum. Chest. 1987 Dec;92(6):1110–1112. doi: 10.1378/chest.92.6.1110. [DOI] [PubMed] [Google Scholar]
  9. Johnson S. M., Roberts G. D. In vitro activity of ciprofloxacin and ofloxacin against the Mycobacterium avium-intracellulare complex. Diagn Microbiol Infect Dis. 1987 May;7(1):89–91. doi: 10.1016/0732-8893(87)90077-0. [DOI] [PubMed] [Google Scholar]
  10. Leysen D. C., Haemers A., Pattyn S. R. Mycobacteria and the new quinolones. Antimicrob Agents Chemother. 1989 Jan;33(1):1–5. doi: 10.1128/aac.33.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lockley M. R., Wise R., Dent J. The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother. 1984 Dec;14(6):647–652. doi: 10.1093/jac/14.6.647. [DOI] [PubMed] [Google Scholar]
  12. Saito H., Sato K., Tomioka H., Watanabe T. [In vitro and in vivo activities of norfloxacin, ofloxacin and ciprofloxacin against various mycobacteria]. Kekkaku. 1987 May;62(5):287–294. [PubMed] [Google Scholar]
  13. Saito H., Tomioka H., Sato K., Emori M., Yamane T., Yamashita K., Hosoe K., Hidaka T. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother. 1991 Mar;35(3):542–547. doi: 10.1128/aac.35.3.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Smith M. J., White L. O., Bowyer H., Willis J., Hodson M. E., Batten J. C. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1986 Oct;30(4):614–616. doi: 10.1128/aac.30.4.614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tomioka H., Sato K., Saito H. Effect of ofloxacin combined with Lactobacillus casei against Mycobacterium fortuitum infection induced in mice. Antimicrob Agents Chemother. 1990 Apr;34(4):632–636. doi: 10.1128/aac.34.4.632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tomioka H., Sato K., Saito H. [Antimycobacterial activities of a new quinolone, sparfloxacin]. Kekkaku. 1991 Oct;66(10):643–649. [PubMed] [Google Scholar]
  17. Truffot-Pernot C., Ji B., Grosset J. Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments. Tubercle. 1991 Mar;72(1):57–64. doi: 10.1016/0041-3879(91)90025-n. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES